Bagsværd, Denmark, November 3, 2026 – Novo Nordisk A/S has initiated a significant share repurchase program, committing to buy back shares worth up to DKK 15 billion. This program is designed to enhance shareholder value and reflects the company's ongoing commitment to return capital to its investors.

The share repurchase program, which began on May 6, 2026, is set to run for 12 months, concluding on February 1, 2027. Under this program, Novo Nordisk plans to repurchase B shares for a total amount of DKK 11.2 billion, as part of its broader strategy to manage its capital structure and support its share price.

Background

Founded over a century ago, Novo Nordisk A/S is a global healthcare company specializing in the development and production of pharmaceutical preparations, particularly in diabetes care and hormone replacement therapies. The company is listed on the New York Stock Exchange (NVO) and the OTC market (NONOF), and it operates primarily in the pharmaceutical preparations sector, as classified under SIC 2834.

In its recent filings, including the latest one on November 3, 2026, Novo Nordisk has consistently demonstrated its commitment to shareholder returns. The company has been proactive in implementing financial strategies that align with its growth objectives.

What the Filing Says

The company disclosed in its latest filing that since the announcement of the share repurchase program, a total of 41,714,179 B shares have been repurchased at an average price of DKK 277.23 per share, amounting to a transaction value of DKK 11.56 billion. As of November 2, 2026, Novo Nordisk has accumulated a total of 55,754,876 B shares as treasury shares, representing 1.2% of its share capital.

According to the filing, "Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning February 4, 2026." This indicates a robust commitment to enhancing shareholder value through strategic capital management.

Impact

This share repurchase program is likely to have a positive impact on various stakeholders, including investors, analysts, and the broader pharmaceutical industry. Investors may view the program as a sign of confidence in the company's financial health and future prospects. Analysts may interpret this move as a proactive approach to managing capital and enhancing shareholder returns.

Moreover, the pharmaceutical preparations industry may see this as a trend, encouraging other companies within the sector to adopt similar strategies to bolster shareholder confidence and maintain competitive positioning.

What's Next

The filing does not specify what happens next beyond the ongoing share repurchase program. However, investors and analysts will likely be monitoring Novo Nordisk's progress in executing this program and its impact on the company's share price and overall market perception.

For more detailed information on the transactions made under the share repurchase program, Novo Nordisk has indicated that updates will be published on their official website.